Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 21 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 9 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

4Total
Not Applicable (2)
P 1 (1)
P 2 (1)

Trial Status

Completed9
Recruiting7
Active Not Recruiting2
Unknown1
Withdrawn1
Enrolling By Invitation1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 9 completed trials

Clinical Trials (21)

Showing 20 of 20 trials
NCT05204017Recruiting

Comprehensive Analysis Platform To Understand, Remedy and Eliminate ALS

NCT04875416Active Not Recruiting

Phenotype, Genotype and Biomarkers 2

NCT03489278Recruiting

Clinical Procedures to Support Research in ALS

NCT06553976Recruiting

Spastic Paraplegia - Centers of Excellence Research Network

NCT07478172Not ApplicableRecruiting

Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease

NCT02567136Recruiting

Imaging Biomarkers in ALS

NCT03912987Active Not Recruiting

TRIAL READY (Clinical Trial Readiness)

NCT06315673Recruiting

Digital Assessment of Speech and Fine Motor Control in ALS

NCT02327845Enrolling By Invitation

Phenotype, Genotype & Biomarkers in ALS and Related Disorders

NCT06012110Not ApplicableCompletedPrimary

Transcutaneous Electrical Stimulation for Spasticity in Patients With Primary Lateral Sclerosis

NCT06320444Recruiting

Non-invasive Spinal, Cortical, and Sensorimotor Biomarkers in Motor Neurone Disease

NCT05830214Withdrawn

Digital Smartwatch Measurements as Potential Biomarkers for Remote Disease Tracking in ALS

NCT03560661Completed

Acoustic and Perceptual Markers of Dysarthria in Amyotrophic Lateral Sclerosis (ALS)

NCT02574390Completed

Answer ALS: Individualized Initiative for ALS Discovery

NCT00015444CompletedPrimary

Screening and Natural History: Primary Lateral Sclerosis and Related Disorders

NCT01143428Completed

Oxidative Stress in Motor Neuron Disease: COSMOS Add-On Study

NCT02852278Completed

A Patient Centric Motor Neuron Disease Activities of Daily Living Scale

NCT03067857Phase 1Unknown

Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease

NCT00677768Completed

Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS)

NCT00324454Phase 2Completed

Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease

Scroll to load more

Research Network

Activity Timeline